Jackie Syrop

Articles by Jackie Syrop

The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, which reauthorizes a sickle cell disease prevention and treatment program and provides grants for research, surveillance, prevention, and treatment of heritable blood disorders, has passed Congress and been signed into law.

Researchers found no evidence that initiation of inhaled corticosteroids or leukotriene receptor antagonist therapy is associated with fewer wheezing/asthma attacks than therapy with a short-acting ß-agonist alone in preschool children with recurrent wheezing/asthma.

How long a person with obstructive sleep apnea (OSA) stops breathing may be a better predictor of mortality risk from OSA in both women and men than the number of times they stop breathing, a new study published in the American Journal of Respiratory and Critical Care Medicine concludes.

The observational, noninterventional study was part of an emicizumab clinical development program in which a daily bleed and medication questionnaire developed by the sponsor on a handheld device was used to prospectively collect data on treatment with factor VIII or bypassing agents in adult and adolescent people with hemophilia A, with and without inhibitors to FVIII.

A new study, published in the International Journal of COPD, concludes that the increase in endothelial microparticles and various microparticles in the systemic circulation that accompanies chronic obstructive pulmonary disease (COPD) can lead to disease exacerbation and could be used as early biomarkers on disease progression.

Treatment with the investigational drug crizanlizumab (SEG101) reduced pain in patients with sickle cell disease (SCD) who were experiencing vaso-occlusive crisis according to posthoc results of the phase II SUSTAIN study published online in The American Journal of Hematology. The study found that more than twice as many patients with SCD treated with crizanlizumab did not experience a VOC compared with those treated with placebo.

Latest Updated Articles



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo